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Abstract
Spinal cord atrophy is one of the hallmarks of amyotrophic lateral sclerosis (ALS); however, it is not routinely
assessed in routine clinical practice. In the present study, we evaluated whether spinal cord cross-sectional area
measured at the foramen magnum level using a magnetic resonance imaging head scan represents a clinically
meaningful measure to be added to the whole-brain volume assessment. Using an active surface approach, we
measured the cord area at the foramen magnum and brain parenchymal fraction on T1-weighted three-dimensional
spoiled gradient recalled head scans in two groups of subjects: 23 patients with ALS (males/females, 13/10; mean ±
standard deviation [SD] age 61.7 ± 10.3 years; median ALS Functional Rating Scale–Revised score 39, range 27–46) and 18
age- and sex-matched healthy volunteers (mean ± SD age 55.7 ± 10.2 years). Spinal cord area at the foramen magnum
was significantly less in patients than in control subjects and was significantly correlated with disability as measured with
the ALS Functional Rating Scale–Revised (ρ = 0.593, p < 0.005). This correlation remained significant after taking into
account inter-individual differences in brain parenchymal fraction (ρ = 0.684, p < 0.001). Our data show that spinal cord
area at the foramen magnum correlates with disability in ALS independently of whole-brain atrophy, thus indicating its
potential as a disease biomarker.
Keywords: Amyotrophic lateral sclerosis (ALS), Cervical cord atrophy, Foramen magnum, Magnetic resonance
imaging (MRI)
Key points
 Both brain and cervical spinal cord atrophy can be
evaluated on the basis of a single three-dimensional
T1-weighted acquisition.
 Spinal cord cross-sectional area at the foramen
magnum is reduced in patients with ALS compared
with healthy control subjects.
 Spinal cord cross-sectional area reduction at the
foramen magnum correlates with clinical severity
scores in ALS.
Background
Amyotrophic lateral sclerosis (ALS) is a degenerative
disease involving both upper and lower motor neurons
and ultimately leads to a fatal outcome in a variably
short period of time (median survival 3 years). After an
insidious and non-specific onset, the patient experiences
progressively worsening functional deficits, such as
weakness; fatigue; muscle atrophy; and, as the diseases
progresses, loss of control of respiratory muscles, which
is the major cause of mortality [1]. Several neuroprotec-
tive agents and neuroregenerative approaches are cur-
rently under study, and their efficacy is being assessed
with functional tests, clinical scales and survival rates.
Magnetic resonance imaging (MRI) of both brain and
spinal cord in ALS [2] offers potentially valuable non-
invasive radiological surrogate biomarkers at levels of
both the whole brain and the region-of-interest [3].
However, even though the spinal cord is affected by ALS
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and is always assessed for diagnostic purposes, it is
rarely investigated in research studies [3, 4]. Despite this,
different studies showed a significant relationship of dis-
ability with MRI metrics of spinal cord damage, such as
diffusion MRI [2, 5], and with cervical cord volume loss,
usually assessed at the C2-C3 level [6].
A recent study proposed to measure the spinal cord
cross-sectional area at the level of the foramen magnum
(foramen magnum cord area [FMCA]) instead of at the
usual C2-C3 level and validated it as a surrogate marker
in multiple sclerosis [7]. A possible advantage of this
approach is the possibility of obtaining a relatively
reliable spinal cord atrophy index from a structural brain
scan without the need to perform a high-resolution
cervical cord acquisition. In fact, even though in most
standard brain three-dimensional T1 scans the C2-C3
level is inconsistently included, the foramen magnum
region, containing the gradual junction between the
caudal medulla oblongata and the rostral cervical cord
(to simplify, hereafter referred as cord), is generally al-
ways included. Therefore, the aims of our present study
were (1) to apply FMCA measures in patients with ALS
and test whether this measure is independent of whole-
brain atrophy, (2) to assess the potential correlation be-
tween FMCA and cord area measured at the C2-C3 level
(C2-C3 area), and (3) to investigate the clinical relevance
of FMCA measures by assessing its relationship with
clinical disability.
Methods
Subjects
Twenty-three subjects (males/females = 13/10; mean ±
standard deviation [SD] age 61.7 ± 10.3 years) diagnosed
with probable or definite ALS according to the El Escorial
revised criteria [8] were enrolled in this study. All patients
were clinically evaluated with the ALS Functional Rating
Scale–Revised (ALSFRS-R) [9], always by the same experi-
enced neurologist, who had 8 years of experience. Eighteen
healthy age- and sex-matched subjects (mean ± SD age 55.
7 ± 10.2 years) not related to the enrolled patients were also
enrolled specifically for this study as a healthy control
group of volunteers. All study procedures were approved by
our institution’s ethics committee and conducted according
to the Declaration of Helsinki. Informed consent to partici-
pate and for publication of the results was acquired from all
participants.
MRI protocol
Within 5 days of clinical evaluation, all subjects underwent
a routine clinical MRI protocol, including a standardized
T1-weighted brain volumetric scan acquired with a 1.5-T
system (SIGNA; General Electric Healthcare, Milwaukee,
WI, USA) using an eight-channel high-resolution brain
array coil. The sequence obtained was a sagittal three-
dimensional spoiled gradient recalled sequence with the fol-
lowing technical parameters: repetition time 28 ms, echo
time 6 ms, flip angle 30 degrees, field of view 256 ×
256 mm, in-plane matrix 256 × 256, slice thickness 1.3 mm.
Patients were standardly positioned with particular care to
avoid neck hyperextension, which is described to cause arti-
facts and unusual inflections of the cord [10, 11]. Foam
pads were placed around the patient’s head to increase
comfort and reduce motion artifacts. All scanned volumes
included the foramen magnum area.
Image analysis
First, all images were visually checked for quality before
analysis. An experienced neuroradiologist with more
than 5 years of experience, who was blinded to group
assignment and to the clinical ALSFRS-R results,
performed the image post-processing as previously
described [7] using Jim software (version 6; Xinapse
Systems, West Bergholt, UK). Briefly, multi-planar
reconstruction of the volumetric T1-weighted scan
was re-oriented on an axial plane in order to obtain a
cross-section of the cord perpendicularly to its long
axis (Fig. 1a, b). A 1.0 × 1.0 × 1.3-mm slice was then
visually identified to isolate the foramen magnum
landmark. At this level, the centre of the cord was
manually marked with a seed point, and the Cord
Finder tool (available in Jim Software) was run to
automatically contour the cord parenchyma (Fig. 1c)
using an active surface algorithm [12]. Each segmen-
tation result underwent an accuracy check and, if
necessary, manual editing. To enhance accuracy, cord
area was assessed via region-of-interest statistics in the
Jim environment on five different contiguous 1.3-mm-
thick parallel slices for each patient starting from the slice
at the foramen magnum and extending downwards.
Moreover, we evaluated on which patients the scan field
of view covered the C2-C3 cord region satisfactorily, and
subsequently we calculated the cord area at that level (C2-
C3 area) using the same procedure applied for FMCA.
From the volume obtained with the same sequence, brain
parenchymal fraction (BPF), defined by the ratio between
brain parenchymal (the sum of white and grey matter)
and intracranial (the sum of white and grey matter and
cerebrospinal fluid) volumes, was estimated for all sub-
jects using the Statistical Parametric Mapping 12 spm_
segment pipeline [13].
Statistical analysis
All statistical analyses were carried out using IBM SPSS
Statistics version 20 software (IBM, Armonk, NY, USA).
FMCA, C2-C3 area and BPF samples were tested for nor-
mality with the Shapiro-Wilk test. An independent sam-
ples t test between the ALS and control groups was
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performed to assess if there were significant differences in
age, BPF and FMCA mean values. Pearson’s correlations
were then used to assess the association between FMCA
and ALSFRS-R and between FMCA and C2-C3 area.
A partial correlation test controlling for BPF values
was performed to test if the FMCA relationship to
ALSFRS-R was independent from inter-individual BPF
variabilities. A further partial correlation test taking
age into account was performed to verify the impact
of age on the FMCA/ALSFRS-R correlation. Data are
reported as mean ± SD.
Results
Clinical evaluation
In our sample, the age of patients and disease duration
were, respectively, 61.7 ± 10.3 years and 9.4 ± 6.4 months.
Clinical evaluation of our group of patients with ALS re-
sulted in a median ALSFRS-R score of 39, with a range
from 27 to 46.
Differences in MRI metrics between patients and control
subjects
In 23 subjects (14 patients and 9 control subjects), the
C2-C3 cord region was consistently included in the MRI
field of view. Overall, 18 cord contours had to be manually
edited. The image processing of each patient required
around 15 minutes. FMCA, C2-C3 area, and BPF values
appeared normally distributed in the patients with ALS
and the healthy control subjects.
The independent samples t test between patients with
ALS and healthy control subjects resulted in a significant
difference in FMCA values: 78.3 ± 9.9 mm2 and 88.9 ± SD
6.0 mm2, respectively (p < 0.001) (Fig. 2a). Conversely,
age and BPF values did not differ significantly between the
patients with ALS and healthy control subjects: 61.7 ±
10.25 years and 55.7 ± 10.2 years, respectively (p= 0.732),
and 0.78 ± 0.06 and 0.79 ± 0.06, respectively (p= 0.331). In the
subsample of 23 subjects in whom C2-C3 area was obtain-
able, C2-C3 area did not differ significantly between patients
and control subjects: 70.27 ± 6.12 mm2 and 74.84 ± 4.9 mm2,
Fig. 1 a and b Three-dimensional T1-weighted images volume-realigned perpendicularly to the main axis of the cord. Re-oriented axial views at
the level of the foramen magnum (c) and at the C2-C3 level (d) depict the medians of five regions of interest for the quantification of cord area
Fig. 2 a Graph depicting significant difference in the foramen magnum cord area (FMCA) (mm2) between the two groups with 95% CIs. b Plot
showing the correlation between FMCA (mm2) and Functional Rating Scale–Revised (ALSFRS-R) values of patients with amyotrophic lateral
sclerosis (ALS)
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respectively (p= 0.077). Because multiple independent
samples t tests were performed, the Bonferroni correction
was applied (with a threshold of p= 0.00125); thus, the
difference in FMCA values remained significant at p= 0.005.
Correlation between clinical and MRI measures
The correlation between FMCA and C2-C3 area (in the
subset of 23 subjects in whom this value was obtainable) was
significant (Pearson’s ρ= 0.778, p < 0.001). The correlation
between ALSFRS-R and FMCA values was significant
(Pearson’s ρ= 0.593, p < 0.005), with subjects presenting with
a more severe ALS clinical disability score having a smaller
FMCA area (Fig. 2b); this correlation remained significant
even after taking into account possible biasing variables such
as age (ρ= 0.550, p= 0.008) and BPF (ρ= 0.684, p < 0.001).
Moreover, the correlation between ALSFRS-R and C2-C3
area (in the 14 patients where applicable) also was significant
(Pearson’s ρ= 0.556, p= 0.039). Results are summarized in
Table 1.
Discussion
Overall, our findings show that FMCA as well as C2-C3
cord area correlates with clinical disability and that the
correlation between FMCA and clinical disability score
is independent of brain atrophy. Furthermore, our data
show that our metric (FMCA) could be assessed with
clinical MRI data more easily than C2-C3 cord area,
which was satisfactorily included only in a limited num-
ber of scans (54%).
Furthermore, though the C2-C3 cord area differed be-
tween patients and control subjects, this difference did
not reach statistical significance, probably due to the
small number of subjects for whom the C2-C3 area was
available compared with the whole study population.
Although atrophy in the cervical cord segment is a key
pathological element of ALS, its optimal visual quantifi-
cation is difficult in clinical practice; therefore, the avail-
ability of an objective parameter to assess spinal cord
volume loss could be very helpful in this context.
To date, in ALS clinical trials, disease severity and
progression have usually been evaluated with clinical
scores and functional tests. The use of these endpoints
typically necessitates long-term assessment of a large
number of patients, consequently increasing the cost of
clinical trials and potentially discouraging the evaluation
of novel treatments, particularly neuroprotective drugs.
Sensitive imaging biomarkers can be useful to this end,
such as by reducing sample size in pilot studies. In ALS,
given the involvement of both the brain and the spinal
cord, a lengthy brain-spinal cord protocol is needed to
evaluate these two regions using available radiological
surrogate markers. Obtaining cord atrophy information
from a fast “single anatomical district” protocol is par-
ticularly advantageous because it spares the necessity
of a dedicated spinal cord acquisition, which would
prolong the scan time, consequently challenging patients
with ALS. Because FMCA can be computed using con-
ventional volumetric head scans, its evaluation could
represent a high-yield addition to clinical and research
imaging protocols to systematically, albeit indirectly,
assess spinal cord volume loss in ALS. Of note, the
computation of FMCA is equally feasible using pre-
viously acquired datasets, which involves the interesting
potential to retrospectively review a large number of
clinical scans.
In this study, we measured FMCA, a straightforward
MRI indicator that requires very light processing time
and basic skills, and we investigated its relationship to
the current clinical scale. Our results are consistent with
literature findings that assess cord atrophy at levels dif-
ferent from the foramen magnum and correlate it with
disability clinical scores in ALS [6].
The independence of FMCA correlation with the clin-
ical marker ALSFRS-R from BPF values confirms the
additional information that this novel measure could
provide in a clinical MRI analysis protocol, suggesting
that a combined imaging biomarker could further im-
prove accuracy in disease monitoring [14] because two
different and complementary sets of information can be
acquired from a single head scan. The advantages in
terms of improved robustness of a brain-cervical com-
posite atrophy marker compared with the single mea-
sures are already validated in the literature for other
neurological conditions [15].
Table 1 Demographics and magnetic resonance imaging results
Patients with ALS Healthy control subjects p Value
Subjects, total (males/females) 23 (13/10) 18 (5/13) –
Age, years, mean ± SD 61.7 ± 10.3 55.7 ± 10.2 0.738
FMCA, mm2, mean ± SD 78.3 ± 9.9 88.9 ± 6.0 < 0.005a
BPF, mean ± SD 0.78 ± 0.06 0.79 ± 0.06 0.336
ALSFRS-R, median; range 39; 27–46 – –
Disease duration, months, mean ± SD 9.43 ± 6.41 – –
Abbreviations: ALS Amyotrophic lateral sclerosis; FMCA Foramen magnum cord area; BPF Brain parenchymal fraction; ALSFRS-R ALS Functional Rating Scale–Revised
a Corrected for multiple comparisons with Bonferroni post hoc test
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A limitation of our study is that it was conducted with
a relatively small number of subjects, partly owing to the
moderate prevalence of the disease and partly to the tol-
erability of MRI acquisitions of patients with ALS;
hence, further analysis of a larger cohort of patients
followed over time is desirable. We acknowledge that
primary motor cortex atrophy could represent a more
precise measure of upper motor neuron degeneration
than BPF [16], and thus future studies are warranted to
explore the relationship between FMCA and primary
motor cortex thickness in ALS. Despite this, given the
focus of the present work on metrics that could easily be
used in clinical practice, we decided to use BPF as a
proxy marker of upper motor neuron pathology because,
to date, thickness-based measures have not been widely
used outside the clinical setting.
We show that FMCA is associated with disability inde-
pendently of BPF. Despite this, we acknowledge that
FMCA (but also C2-C3 area) does not represent a pure
measure of lower motor neuron pathology, given the im-
pact of pyramidal tract volume loss on cord measures.
Future studies whose aim is to compare FMCA with cer-
vical grey matter area are warranted to tease out the
relative role of upper and lower motor neuron pathology
in FMCA changes. We also acknowledge that FMCA
cannot be considered a pure measure of upper and
lower motor neuron degeneration; however, our data
show that FMCA conveys information different from
BPF (which is widely used as a proxy of upper motor
neuron degeneration in ALS [17]) and it is more easily
quantifiable in clinical imaging than C2-C3 area.
In conclusion, our data show that FMCA correlates
with disability in patients with ALS independently of
whole-brain atrophy, thus suggesting that it could be
considered as a disease biomarker with the potential to
become a surrogate endpoint in research trials, possibly
alongside other clinical and imaging tools, in order to
create composite indicators of damage.
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